Acute Ischemic Stroke - Pipeline Insight, 2024

This “Acute Ischemic Stroke- Pipeline Insight, 2024” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Ischemic Stroke: Understanding

Acute Ischemic Stroke: Overview

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7, 00,000 people each year. Signs and symptoms of stroke may include sudden-onset numbness or weakness in an arm or leg, facial droop, difficulty speaking or understanding speech, confusion, trouble with balance or coordination, and loss of vision. Acute ischemic stroke is sometimes preceded by a transient ischemic attack (TIA), which is a temporary episode of brain dysfunction due to decreased blood flow. The primary risk factor for acute ischemic stroke is high blood pressure. Other conditions associated with an increased risk of stroke include history of TIAs, cigarette smoking, high cholesterol, diabetes, obesity, end-stage kidney disease, and a heart rhythm disorder called atrial fibrillation. In the US, computed tomography (CT) of the brain is typically the first imaging study used to detect stroke. The CT scan is widely available in hospitals, can be performed quickly, and can detect whether there is bleeding in the brain, which requires different treatment than acute ischemic stroke. Brain magnetic resonance imaging (MRI) is also commonly used to diagnose acute ischemic stroke. Acute ischemic stroke should be treated as soon as possible because earlier treatment is associated with improved outcomes. If acute ischemic stroke is diagnosed early (within 4.5 hours of onset of stroke symptoms), some patients may be eligible for treatment with an intravenous drug that dissolves blood clots, called recombinant tissue plasminogen activator (alteplase). Alteplase decreases the risk of long-term disability after acute ischemic stroke but is associated with about a 6% risk of bleeding in the brain. Moreover, depending on which artery in the brain is blocked, alteplase restores blood flow to the brain in an estimated 10% to 50% of cases. The goal of therapy in acute ischemic stroke is to preserve tissue in areas where perfusion is decreased but sufficient to avoid infarction. Tissue in this area of oligemia is preserved by restoring blood flow to the compromised regions and improving collateral flow. Recanalization strategies include recombinant tissue-type plasminogen activator. Restoring blood flow can minimize the effects of ischemia only if performed quickly.

Acute Ischemic Stroke- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines. The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke.

Acute Ischemic Stroke Emerging Drugs Chapters

This segment of the Acute Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Ischemic Stroke Emerging Drugs

Nelonemdaz: GNT PharmaNelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major routes of brain cell death leading to disability and death after stroke. Nelonemdaz previously showed better efficacy and a longer therapeutic time window than subtype-unselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two earlier phase I studies conducted in 165 healthy young and elderly volunteers in the US and China.

Tenecteplase: GenentechTenecteplase (TNKase, TNK-tPA or TNK) is a thrombolytic agent derived from the tissue plasminogen activator (tPA), that binds fibrin and converts plasminogen to plasmin. It is a 527-amino acid glycoprotein developed by replacing three amino acids at the T, N and K positions of the glycoprotein structure of tPA under genetic recombinant technology. After replacing threonine 103 with asparagine, asparagine 117 with glutamine and a tetra-alanine at amino acids 296-299, TNK is about eightfold more potent in dissolving clot, 80-fold higher resistance to plasminogen activator inhibitor-1 and 14-fold enhanced relative fibrin specificity, and with a longer half-life (20 min).Hence, TNK is administered as a single intravenous bolus. Tenecteplase has a well-characterized mechanism of action with important practical advantages in administration and superior clinical efficacy for patients with large-vessel occlusion. It is currently being evaluated in imaging-eligible, late-window acute ischemic stroke (AIS) patients.

SP-8203: Shin Poong PharmaceuticalSP-8203, under development, is a new neuroprotective compound for acute ischemic stroke. It is a quinazoline-2, 4-dione derivative with multiple potent neuroprotective mechanisms of action including anti-inflammatory activities. Patent applications have been filed in 52 countries and granted in 44 countries. SP-8203, has proved as a first-in-class candidate which has a multiple neuroprotective effects through a variety of the stroke animal models. Particularly, because it extends the therapeutic window when combined with tPA, more patients would have the benefit of reducing cerebral infarction and edema as well as hemorrhage and mortality. In fact, a few years following by the project outset, SP-8203 won the top 10 future pharmaceutical special projects run by the Ministry of Health and Welfare, because it was highly evaluated for its distinctiveness. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

NONO-SC: NoNO Inc.NoNO-SC is a subcutaneously injectable nerinetide analog for the treatment of all strokes. Autoinjector compatibility (i.e. a “stroke pen”) enables administration by any caregiver at home, en route to the hospital or upon arrival in the emergency department. Currently, the drug is in Preclinical stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

Acute Ischemic Stroke: Therapeutic Assessment

This segment of the report provides insights about the different Acute Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Ischemic Stroke

There are approx. 35+ key companies which are developing the therapies for Acute Ischemic Stroke. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, GNT Pharma.

Phases

This report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Ischemic Stroke: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Ischemic Stroke therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Ischemic Stroke drugs.

Acute Ischemic Stroke Report Insights

• Acute Ischemic Stroke Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Ischemic Stroke Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Ischemic Stroke drugs?
• How many Acute Ischemic Stroke drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Ischemic Stroke?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Ischemic Stroke and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Genentech
• Supergene
• Tasly Pharmaceutical
• Pharmazz
• GNT Pharma
• NoNO
• Angde Biotech Pharmaceutical
• NuvOx Pharma
• Healios
• Acticor Biotech
• Biogen
• ZZ Biotech
• Revalesio Corporation
• Shionogi & Co., Ltd.
• AbbVie
• Pharming Group
• Bristol-Myers Squibb
• Roche
• Clinuvel Pharmaceuticals
• TrueBinding
• Shin Poong Pharmaceutical
• Lumosa Therapeutics
• NC Medical Research
• JCR Pharmaceuticals
• aptaTargets
• PT. Prodia Stem Cell Indonesia

Key Products

• Tenecteplase
• Recombinant staphylokinase
• Prourokinase recombinant
• Sovateltide
• Nelonemdaz
• Nerinetide
• Reteplase
• DDFPe
• Invimestrocel
• ACT-017
• TMS-007
• 3K3A-APC
• RNS60
• S-005151
• Elezanumab
• Conestat Alfa
• BMS-986177
• Balovaptan
• Scenesse (Afamelanotide)
• TB006
• SP-8203
• LT 3001
• NCS 01
• JTR-161
• ApTOLL
• Umbilical Cord Mesenchymal Stem Cells

This product will be delivered within 1-3 business days.